The countdown has started to the launch of a new campaign aimed at giving long-term warfarin patients greater choice in the management of their condition.
There are more than 1.2 million people in the UK on warfarin of which less than two per cent benefit from self-monitoring, despite evidence that it can cut the risk of death by nearly two-fifths and more than halve the risk of strokes. The AntiCoagulation Self-Monitoring Alliance (ACSMA) is launching a new campaign with the specific objective of achieving greater access via prescription to INR self-monitoring technology for patients receiving warfarin therapy.The alliance is also seeking to raise awareness of the benefits of self-monitoring and aims to ensure that patients are equipped to have informed discussions with their healthcare professionals on this topic.
The campaing will launch in the House of Commons on 24th October 2012.
We will keep you up to date and informed about how you can support this campaign.
Read more about it at: